Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001144204-18-048704
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-09-07 21:55:14
Reporting Period:
2018-09-05
Accepted Time:
2018-09-07 21:55:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1175151 Cytosorbents Corp CTSO Surgical & Medical Instruments & Apparatus (3841) 980373793
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1442786 P. Phillip Chan C/o Cytosorbents Corporation
7 Deer Park Drive, Suite K
Monmouth Junction NJ 08852
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-09-05 600 $2.00 438,881 No 4 M Direct
Common Stock Acquisiton 2018-09-05 5,187 $2.10 444,068 No 4 M Direct
Common Stock Acquisiton 2018-09-06 2,900 $2.10 446,968 No 4 M Direct
Common Stock Acquisiton 2018-09-07 2,731 $2.10 449,699 No 4 M Direct
Common Stock Disposition 2018-09-05 600 $14.85 449,099 No 4 S Direct
Common Stock Disposition 2018-09-05 5,187 $14.85 443,912 No 4 S Direct
Common Stock Disposition 2018-09-06 2,900 $14.75 441,012 No 4 S Direct
Common Stock Disposition 2018-09-07 2,731 $14.11 438,281 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Statutory Stock Option (right to buy) Acquisiton 2018-09-05 600 $0.00 600 $2.00
Common Stock Non-Statutory Stock Option (right to buy) Acquisiton 2018-09-05 5,187 $0.00 5,187 $2.10
Common Stock Non-Statutory Stock Option (right to buy) Acquisiton 2018-09-06 2,900 $0.00 2,900 $2.10
Common Stock Non-Statutory Stock Option (right to buy) Acquisiton 2018-09-07 2,731 $0.00 2,731 $2.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2008-12-31 2018-12-31 No 4 M Direct
94,968 2019-01-08 No 4 M Direct
92,068 2019-01-08 No 4 M Direct
89,337 2019-01-08 No 4 M Direct
Footnotes
  1. Includes (i) the following restricted stock units (RSUs) that will be settled into common stock upon vesting upon a "Change In Control," as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 18,700 RSUs granted on February 24, 2017, (b) 57,000 RSUs granted on June 7, 2016, (c) 130,000 RSUs granted on April 8, 2015, and (d) 10,300 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 13,542 RSUs granted on February 24, 2017 which are unvested as of the date hereof, and (b) 28,667 RSUs granted on February 28, 2018 which are unvested as of the date hereof and (iii) shares of common stock owned by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.10 to $14.15, inclusive.
  3. The option, representing a right to purchase a total of 100,155 shares, became exercisable per the following vesting schedule: fifty percent (50%) of the shares of common stock underlying the option vested on January 8, 2009, with the remaining fifty percent (50%) vesting at the discretion of the Issuer's Compensation Committee based on criteria including (but not limited to) success relative to (i) a timely completion of the Issuer's sepsis trial, (ii) raising capital for the Issuer, and (iii) partnering and business development; provided, however, that, in no event shall the vesting of all of the remaining fifty percent (50%) occur later than January 1, 2010.